Skip to main content
. Author manuscript; available in PMC: 2022 May 6.
Published in final edited form as: Am J Transplant. 2020 Aug 9;21(4):1477–1492. doi: 10.1111/ajt.16174

FIGURE 3.

FIGURE 3

A, Mean glucose levels (mg/dL). The Wilcoxon signed rank test for paired outcomes was used to compare mean continuous glucose monitoring system (CGMS®) glucose (mg/dL) from baseline to day 365, day 730, and day 1095 following initial purified human pancreatic islets (PHPI) product transplant. The Benjamini-Hochberg (BH) method was used to adjust the level of significance to preserve the overall false discovery rate of 10%. The upper BH boundary was 0.0794 and the P values for the 2-sided Wilcoxon signed rank tests were P = .0625 for day 365, P = .0156 for day 730, and P = .0625 for day 1095. B, Average SD of glucose levels (mg/dL). The Wilcoxon signed rank test for paired outcomes was used to compare average SD of glucose levels (mg/dL) from baseline to day 365, day 730 and day 1095 following initial PHPI product transplant. The BH method was used to adjust the level of significance to preserve the overall false discovery rate (FDR) of 10%. The upper BH boundary was 0.0794 and the P values for the 2-sided Wilcoxon signed rank tests were P = .0625 for day 365, P = .0156 for day 730, and P = .0625 for day 1095. C, Percent of time in glucose range. The Wilcoxon signed rank test for paired outcomes was used to compare CGMS® percent excursions for < 54, within (54-180), and >180, from baseline to day 365, day 730, and day 1095 following initial PHPI product transplant. The BH method was used to adjust the level of significance to preserve the overall FDR of 10%. The upper BH boundary was 0.0794 and the P values for the 2-sided Wilcoxon signed rank tests were, respectively, P = .2500, P = .0625 and P = .0625 for day 365; P = .1250, P = .0156, and P = .0156 for day 730; and P = .7500, P = .0625, and P = .0625 for day 1095. D, Glucose level (mg/dL) number of excursions < 54 mg/dL per 24 h. The Wilcoxon signed rank test for paired outcomes was used to compare the median number of hypoglycemic excursions per day from baseline to day 365, day 730, and day 1095 following initial PHPI product transplant. The BH method was used to adjust the level of significance to preserve the overall FDR of 10%. The upper BH boundary was 0.0794 and the P values for the 2-sided Wilcoxon signed rank tests were P = .2500 for day 365, P = .1250 for day 730, and P = 1.0 for day 1095